R emyelination restores rapid transmission of nerve impulses and axonal function in the central nervous system (CNS) of patients with demyelinating diseases such as multiple sclerosis (MS). Although remyelination can occur in MS, age-associated decline in myelin repair contributes to chronic progressive disease and disability (1) . Thus, understanding the cause of and preventing this decline are key goals in regenerative medicine (2) (3) (4) . So far, epigenetic changes within aging oligodendrocyte progenitor cells and declines in phagocytic capacity of aged blood-derived monocytes have been identified as possible mechanisms (5, 6) . We implemented a toxin-induced model, in which a single injection of lysolecithin (lysophosphatidylcholine) induces a focal demyelinating lesion in the white matter of the brain or spinal cord of mice. In lesioned animals, demyelination is complete within 4 days, followed by a repair process that is maximal between 14 and 21 days postinjection (dpi) and requires rapid clearance of damaged myelin for regeneration to occur (7) .
We induced focal demyelinating lesions in the corpus callosum of young (3 months) and old (12 months) mice by lysolecithin injections. Lesions were of similar size at 4 dpi but not at 14 dpi, confirming the poor regenerative capacity of old mice (Fig. 1 , A to C, and fig. S1, A to E). Sustained immune infiltration, as determined by IBA1-positive and MAC2-positive cells, was detected in old mice at 14 dpi (Fig. 1, A and E, and  fig. S1G ). Myelin debris accumulation within lysosomes of phagocytes (Fig. 1, D and F) and numerous foam cells harboring lipid droplets and needle-shaped cholesterol crystals-a typical hallmark of cholesterol overloading-were found in old mice (Fig. 1, G and H, and fig. S2G ). Moreover, by a combination of laser reflection and fluorescence confocal microscopy (reflection microscopy) we confirmed the increase of crystal deposition in spinal cord lesions of old mice (Fig. 1, I and J). Crystals were similarly observed in two other models of myelin injury ( fig. S2 ).
Toxic overload of cholesterol drives the formation of foamy macrophages and maladaptive immune responses in atherosclerosis. We hypothesized that the accumulation of cholesterol, the major component of myelin, may overwhelm the cholesterol transport capacity of phagocytes, thereby forming a bottleneck for successful repair in the aged CNS. Because cholesterol cannot be broken down, it must be transferred from the phagocytes back to the extracellular space via the transporters ABCA1 and ABCG1 [adenosine triphosphate-binding cassette (ABC) A1 and G1] in the plasma membrane where it binds highdensity lipoprotein particles [e.g., apolipoprotein E (APOE)] (8) . Real-time quantitative reverse transcription polymerase chain reaction (PCR) analyses revealed that the expression of ApoE, Abca1, and Abcg1 was reduced in 4-dpi lesions of old mice compared with young mice (Fig. 1, K to M, and  fig. S3 ). Oxysterols (hydroxylated cholesterol metabolites) such as 24S-and 27-hydroxycholesterol are endogenous ligands for the liver X receptor (LXR), thereby controlling the expression of genes involved in cholesterol efflux in cholesterol-loaded cells (9) . Relative amounts of 24S-hydroxycholesterol did not differ in lesions of young and old animals, but 27-hydroxycholesterol levels were reduced in lesions of old mice ( fig. S3 ). One possible explanation for lesion restitution failure in old mice is the inability to clear excessive myelin-derived cholesterol from phagocytes. Thus, we examined whether the LXR agonist GW3965 (10) improve lesion recovery in old mice by inducing the expression of genes involved in lipid efflux, such as Abca1, Abcg1, and ApoE ( fig. S3 ). GW3965 led to markedly improved lesion regeneration in old mice, with a reduction in the number of IBA1-positive and MAC2-positive phagocytes (Fig. 1, A to C) . In addition, the number of phagocytes containing myelin debris, the number of foam cells, and the amount of cholesterol crystals were reduced by treatment with GW3965 ( Fig. 1, A to J) .
Because accumulation of cholesterol in phagocytes may pose a barrier for successful tissue regeneration, we analyzed the regenerative capacity of mouse mutants lacking central factors of the reverse cholesterol transport pathway. We induced demyelinating lesions in 3-month-old NR1H3 (or LXRa) knockout (KO) mice and observed, as in aged wild-type (WT) mice, impaired lesion restitution and sustained phagocyte infiltration at 21 dpi ( fig. S4 , A to C). In addition, we detected accumulation of myelin debris in lysosomes of phagocytes and crystal deposition in lesions of LXRa KO mice ( fig. S4 , D to G).
Next, we analyzed the role of APOE, the major CNS cholesterol carrier that supports lipid efflux from cells (11) . We induced focal demyelination in the corpus callosum of 12-week-old APOE KO and WT control mice and quantified lesion size and recovery. Lesion size did not differ initially, at 4 dpi ( fig. S4 , H to J). However, when lesions were analyzed at 21 dpi, we observed impaired lesion restitution. We detected increased numbers of IBA1-positive, MAC2-positive, and major histocompatibility complex class II (MHC II)-positive phagocytes, as well as enhanced crystal deposition and myelin debris accumulation within lysosomes of phagocytes in spinal cord and corpus callosum lesions of APOE KO animals as compared with control mice (Fig. 2 and fig. S5 ). Because APOE has functions beyond cholesterol transport (11), we tested the efficacy of cyclic oligosaccharide 2-hydroxypropyl-b-cyclodextrin (HbCD), a compound that increases cholesterol efflux and solubility (12) , and found that HbCD treatment attenuated the phenotype of APOE KO animals ( Fig. 3 and fig. S6 ).
Together with Abca1 and Abcg1, ApoE represents one of the major nuclear LXR-regulated genes involved in mediating cholesterol efflux from phagocytes. We thus crossbred CX3CR1CreER animals with Abca1 fl/fl and Abcg1 fl/fl mice to obtain microglia-and macrophage-specific double-KO mice (ABCA1 and ABCG1 KO). We observed an increased number of IBA1-positive and MHC II-positive phagocytes, an increase in crystal deposition, and fewer myelinated axons in 21-dpi lesions of ABCA1 and ABCG1 KO animals as compared with controls ( fig. S7) .
Because excessive cholesterol accumulation in phagocytes limits lesion recovery, we turned to cell culture experiments to determine the mechanisms involved. We prepared phagocytes [primary microglia or bone marrow-derived macrophages (BMDMs)] from APOE KO and WT mice and examined the phagocytic uptake of myelin debris, which did not differ in cells prepared from WT or APOE KO mice ( fig. S8, A and B). Because APOE is also produced by astrocytes, we incubated cells in the presence of serum-free conditioned media prepared from either WT or APOE KO astrocytes and observed the clearance of the internalized myelin particles from phagocytes. Myelin debris persisted within lysosomes of APOE KO cells that were incubated with conditioned media from APOE KO astrocytes. Clearance could be improved by an APOEderived mimetic peptide, ATI5261 (13) , which contains an amphipathic a-helical motif responsible for lipid binding and cholesterol efflux (Fig. 3,  E and F) . Moreover, myelin debris treatment resulted in crystal formation, which was increased in APOE KO macrophages and reduced by GW3965 treatment ( fig. S8 , C to G). In atherosclerosis, cholesterol crystals can induce inflammation by phagolysosomal membrane rupture and subsequent stimulation of the caspase-1-activating NLRP3 (NALP3 or cryopyrin) inflammasome and secretion of interleukin (IL)-1 cytokines (14, 15) . Myelin debris treatment resulted in lysosomal permeabilization and caspase-1 cleavage in WT but not in NLRP3-deficient macrophages (Fig. 4, A to H, and fig. S9,   A and B) . More pronounced caspase-1 activation was observed in APOE KO as compared with WT macrophages, which was confirmed in vivo in APOE KO mice after lysolecithin injection (Fig.  4E and fig. S9C ). Myelin overloading induced cell death, which resulted in DNA fragmentation [detected by TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay], was cholesterol dependent ( fig. S9, D and E) , and was rescued by caspase-1 inhibitors, pointing to an inflammasomemediated pyroptotic cell death pathway (Fig. 4G   and fig. S10 ). Thus, cholesterol derived from myelin debris can activate the NLRP3 inflammasome in macrophages when toxic levels build up intracellularly in the absence of sufficient lipoprotein carriers.
Because jamming the lysosomal system with myelin debris resulted in cholesterol crystallization and inflammasome activation, we asked whether this pathway was responsible for limiting regeneration in old mice. To examine whether increased inflammasome activation contributed to the poor recovery of old mice, we Cantuti analyzed spinal cord lesions of aged WT and NLRP3-deficient mice. As in GW3965-treated old animals (Fig. 4, I and J), we found significantly improved remyelination in aged NLRP3-deficient mice as compared with aged WT mice at 21 dpi. Thus, inflammasome activation, possibly downstream of cholesterol accumulation, drives a maladaptive immune response that hampers inflammation resolution and repair in aged mice. Self-resolving inflammation is essential for a proper restorative process after tissue damage, whereas uncontrolled inflammation can leave lasting marks that permanently alter tissue homeostasis (16) . We made the surprising discovery that the self-limiting inflammatory response, which is necessary to initiate a regenerative process, is maladaptive in the CNS of aged mice. It appears that the inability of aged phagocytes to clear the enormous amounts of cholesterol that are released from myelin after myelin breakdown in demyelinating diseases results in a phase transition of free cholesterol into crystals, inducing lysosomal rupture and inflammasome stimulation, consistent with the beneficial effects of nuclear receptor agonists in remyelination (17, 18) . The unexpected link between lipid metabolisms and tissue regeneration provides opportunities for the development of regenerative medicines for remyelination and for improving functional recovery after CNS injury (19) .
